Horiguchi M - Search Results

1

PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.

Sandoval RL, Horiguchi M, Ukaegbu C, Furniss CS, Uno H, Syngal S, Yurgelun MB. Sandoval RL, et al. Among authors: horiguchi m. Fam Cancer. 2023 Oct;22(4):459-465. doi: 10.1007/s10689-023-00345-0. Epub 2023 Aug 12. Fam Cancer. 2023. PMID: 37572151

2

Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Horiguchi M, Uno H, Wei LJ. Horiguchi M, et al. J Clin Oncol. 2017 Oct 10;35(29):3373. doi: 10.1200/JCO.2017.73.8120. Epub 2017 Aug 11. J Clin Oncol. 2017. PMID: 28800271 No abstract available.

3

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.

Horiguchi M, Uno H, Wei LJ. Horiguchi M, et al. J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337638 No abstract available.

4

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.

Horiguchi M, Uno H, Wei LJ. Horiguchi M, et al. J Clin Oncol. 2018 Mar 10;36(8):825-826. doi: 10.1200/JCO.2017.75.9829. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373099 No abstract available.

5

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.

Horiguchi M, Cronin AM, Takeuchi M, Uno H. Horiguchi M, et al. Stat Med. 2018 Jul 10;37(15):2307-2320. doi: 10.1002/sim.7661. Epub 2018 Apr 22. Stat Med. 2018. PMID: 29682762

6

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study.

Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ. Horiguchi M, et al. JAMA Oncol. 2018 Jun 1;4(6):881-882. doi: 10.1001/jamaoncol.2018.0518. JAMA Oncol. 2018. PMID: 29801103 Free PMC article.

7

How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Horiguchi M, Hassett MJ, Uno H. Horiguchi M, et al. Oncologist. 2019 Jul;24(7):867-871. doi: 10.1634/theoncologist.2018-0141. Epub 2018 Sep 10. Oncologist. 2019. PMID: 30201741 Free PMC article.

8

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.

Uno H, Horiguchi M, Hassett MJ. Uno H, et al. Among authors: horiguchi m. Oncologist. 2020 Feb;25(2):91-93. doi: 10.1634/theoncologist.2019-0464. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32043795 Free PMC article.

9

On permutation tests for comparing restricted mean survival time with small sample from randomized trials.

Horiguchi M, Uno H. Horiguchi M, et al. Stat Med. 2020 Sep 10;39(20):2655-2670. doi: 10.1002/sim.8565. Epub 2020 May 20. Stat Med. 2020. PMID: 32432805

10

Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.

Horiguchi M, Hassett MJ, Uno H. Horiguchi M, et al. Clin Trials. 2020 Dec;17(6):597-606. doi: 10.1177/1740774520940256. Epub 2020 Sep 15. Clin Trials. 2020. PMID: 32933339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters